Welcome to the March 2021 edition of the Covance DCT blog. This month, we want to highlight the growing connections between decentralized clinical trials (DCTs) and the critical therapeutic area of oncology.

Insights From Our Labs to Yours
Covance by LabCorp Blog
Welcome to the March 2021 edition of the Covance DCT blog. This month, we want to highlight the growing connections between decentralized clinical trials (DCTs) and the critical therapeutic area of oncology.
Welcome to the February 2021 edition of the Covance by Labcorp Decentralized Clinical Trials Blog. Most of our blogs focus on interesting things we hear from sponsors, new developments at Covance by Labcorp, or interesting challenges we encounter as we partner with sponsors. This month, however, we want to take …
Understanding the expectations and challenges The pharmaceutical and medical device industries are seeing a substantial increase in combination products, and the related regulatory environment has been very dynamic. Recently, I was privileged to moderate a PharmaVOICE webinar on the latest U.S. FDA post-marketing safety reporting (PMSR) ruling and guidance. Expert …
Weathering natural disasters and the COVID-19 pandemic To drive speed to therapy, reduce financial burdens and empower patient engagement, a Patient Support Services Call Center provides myriad support services that stakeholders depend upon. For pharmaceutical manufacturers, these services have gone from “nice to have” to “must-have,” driven by the growth …
You and your team have been working hard to gain approval and successfully launch your device. However, you may be forgetting an important consideration for market success: reimbursement.
Technology is front and center of patient support programs today, but it isn’t a silver bullet. We need to balance technology with people and processes to achieve the right equilibrium of efficiency and risk.
Introduction Recently, I was privileged to act as the moderator for a World Drug Safety Congress webinar exploring current considerations for developing and testing COVID-19 vaccine solutions at pandemic speed. Our panel of experts included: